Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.2 USD | -0.31% | -8.83% | +4.97% |
May. 16 | Aileron Therapeutics, Inc. Announces Chief Financial Officer Changes | CI |
May. 16 | Aileron Therapeutics, Inc. Announces Executive Changes | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 67.65M |
---|---|---|---|---|---|
Net income 2024 * | -23M | Net income 2025 * | -27M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.88
x | P/E ratio 2025 * |
-1.77
x | Employees | 15 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.51% |
Latest transcript on Aileron Therapeutics, Inc.
1 day | -0.31% | ||
1 week | -8.83% | ||
1 month | -29.67% | ||
3 months | -35.22% | ||
6 months | +50.94% | ||
Current year | +4.97% |
Managers | Title | Age | Since |
---|---|---|---|
Brian Windsor
CEO | Chief Executive Officer | 57 | 23-10-30 |
David Annis
CTO | Chief Tech/Sci/R&D Officer | 51 | 07-10-31 |
Director/Board Member | 53 | 14-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 68 | 19-06-18 | |
Alan Musso
BRD | Director/Board Member | 62 | 23-10-30 |
Brian Windsor
CEO | Chief Executive Officer | 57 | 23-10-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 3.2 | -0.31% | 24,872 |
24-05-30 | 3.21 | -2.43% | 36,412 |
24-05-29 | 3.29 | -3.52% | 28,199 |
24-05-28 | 3.41 | -2.85% | 86,136 |
24-05-24 | 3.51 | -4.10% | 104,596 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.97% | 67.65M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- ALRN Stock